Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07649161 · ClinicalTrials.gov registry record · NA
Nicotinamide Riboside, Vit B3 Analogue, and Brain Energy Metabolism
A NA study, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT07649161: Recruiting NA study, sponsored by Massachusetts General Hospital.
NCT07649161 is a NA study that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07649161, a NA study, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn how nicotinamide riboside (NR), a form of vitamin B3, affects brain energy metabolism in healthy adults. Researchers want to find out if taking NR by mouth for 2 weeks can raise the balance of two related brain chemicals called NAD+ and NADH, which play a key role in how cells make and use energy. The main questions are: Does short term NR treatment increase the NAD+ to NADH ratio in the brain, and does it change other brain energy measures that we can see with a special type of MRI scan called phosphorus 31 MR spectroscopy. Adults between 18 and 65 years old who are generally healthy and do not have a personal or close family history of mood or psychotic disorders may be able to take part. People who join the study will first have a screening visit with a psychiatric interview and safety checks to confirm they are eligible and to review the risks and procedures. Eligible participants will then have a baseline visit that includes a blood draw, vital signs, urine drug and pregnancy tests when needed, and a 7 Tesla MRI/MRS scan focused on brain chemistry and structure. After the baseline visit, participants will take NR capsules by mouth at home, 1500 milligrams in the morning and 1500 milligrams in the early afternoon each day, for about 2 weeks, for a total daily dose of 3000 milligrams. They will be asked to avoid alcohol and other drugs during the study and to complete a short food diary near the end of the dosing period so that researchers can track diet. On the last day of taking NR, participants will return for repeat MRI/MRS scans, blood tests, and vital signs so that researchers can compare brain and blood measures before and after NR treatment. Researchers will compare each participant's brain NAD+ to NADH ratio and other bioenergetic markers before and after NR to see if NR changes these measures in a consistent way. If NR raises brain NAD+ and improves measures of energy metabolism in healthy adults, this may
Interventions
- DIETARY_SUPPLEMENT Niagen®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07649161
The ClinicalTrials.gov registry entry for NCT07649161 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Niagen® is the first listed.
NCT07649161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07649161 about?
NCT07649161 is a clinical study titled "Nicotinamide Riboside, Vit B3 Analogue, and Brain Energy Metabolism". The goal of this clinical trial is to learn how nicotinamide riboside (NR), a form of vitamin B3, affects brain energy metabolism in healthy adults. Researchers want to find out if taking NR by mouth for 2 weeks can raise the balance of two related brain chemicals called NAD+ and NADH, which play a ...
What is the current status of trial NCT07649161?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2026-06. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07649161?
The interventions under investigation include: Niagen® (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07649161?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.